Open Access Repository

Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice

Downloads

Downloads per month over past year

Gurung, RL, Fitzgerald, LM ORCID: 0000-0002-6882-2698, McComish, BJ ORCID: 0000-0003-1940-0007, Hewitt, AW ORCID: 0000-0002-5123-5999, Verma, N and Burdon, KP ORCID: 0000-0001-8217-1249 2021 , 'Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice' , BMJ Open Ophthalmology, vol. 6, no. 1 , pp. 1-10 , doi: 10.1136/bmjophth-2021-000749.

[img]
Preview
PDF
144725 - compar...pdf | Download (377kB)

| Preview

Abstract

Objective: To compare the visual outcomes of intravitreal antivascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in a real-world setting.Methods and analysis: Retrospective analysis of data from the Tasmanian Ophthalmic Biobank database. The median change in best-corrected visual acuity (BCVA) between baseline and 12 months post initiating intravitreal anti-VEGF treatment were compared between the three diseases. Final BCVA, central macular thickness (CMT), cumulative number of injections and overall predictors of change in BCVA and CMT were also determined.Results: At 12 months, change in BCVA was significantly different between nAMD, DMO and RVO cohorts (p=0.032), with lower median change for DMO (2 letters, range -5 to 20) than for RVO (11 letters, range -20 to 35). Likewise, CMT change was significantly different between the three cohorts (p=0.022), with a smaller reduction in CMT in DMO (-54 µm, range -482 to 50) than RVO patients (-137 µm, range -478 to 43; p=0.033). Total number of injections received (p=0.028) and final BCVA score (p=0.024) were also significantly different between the groups. Baseline BCVA was a negative predictor (p=0.042) and baseline CMT a positive predictor (pConclusions:At the end of 12 months, nAMD and RVO cohorts had the greatest improvement in BCVA, however the final BCVA for DMO was significantly better than for nAMD.

Item Type: Article
Authors/Creators:Gurung, RL and Fitzgerald, LM and McComish, BJ and Hewitt, AW and Verma, N and Burdon, KP
Keywords: angiogenesis, vision, anti-VEGF, neovascular age-related macular degeneration, diabetic macular oedema, retinal vein occlusion
Journal or Publication Title: BMJ Open Ophthalmology
Publisher: BMJ Publishing Group Ltd.
ISSN: 2397-3269
DOI / ID Number: 10.1136/bmjophth-2021-000749
Copyright Information:

Copyright 2021 the Author(s) or their employer(s). Licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP